213 related articles for article (PubMed ID: 34326140)
21. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.
Kenny JR; Mukadam S; Zhang C; Tay S; Collins C; Galetin A; Khojasteh SC
Pharm Res; 2012 Jul; 29(7):1960-76. PubMed ID: 22415140
[TBL] [Abstract][Full Text] [Related]
22. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
Waters NJ
Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
[TBL] [Abstract][Full Text] [Related]
24. Mechanistic insights on clearance and inhibition discordance between liver microsomes and hepatocytes when clearance in liver microsomes is higher than in hepatocytes.
Keefer C; Chang G; Carlo A; Novak JJ; Banker M; Carey J; Cianfrogna J; Eng H; Jagla C; Johnson N; Jones R; Jordan S; Lazzaro S; Liu J; Scott Obach R; Riccardi K; Tess D; Umland J; Racich J; Varma M; Visswanathan R; Di L
Eur J Pharm Sci; 2020 Dec; 155():105541. PubMed ID: 32927071
[TBL] [Abstract][Full Text] [Related]
25. Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.
Albaugh DR; Fullenwider CL; Fisher MB; Hutzler JM
Drug Metab Dispos; 2012 Jul; 40(7):1336-44. PubMed ID: 22490230
[TBL] [Abstract][Full Text] [Related]
26. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
27. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
[TBL] [Abstract][Full Text] [Related]
28. Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Cheng Y; Ma L; Chang SY; Humphreys WG; Li W
Drug Metab Dispos; 2016 Aug; 44(8):1372-80. PubMed ID: 27226352
[TBL] [Abstract][Full Text] [Related]
29. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
30. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
[TBL] [Abstract][Full Text] [Related]
31. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
32. Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes.
Chapron B; Risler L; Phillips B; Collins C; Thummel K; Shen D
J Pharm Pharm Sci; 2015; 18(1):101-11. PubMed ID: 25877445
[TBL] [Abstract][Full Text] [Related]
33. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
34. In Vitro-In Vivo Extrapolation and Scaling Factors for Clearance of Human and Preclinical Species with Liver Microsomes and Hepatocytes.
Tess D; Chang GC; Keefer C; Carlo A; Jones R; Di L
AAPS J; 2023 Apr; 25(3):40. PubMed ID: 37052732
[TBL] [Abstract][Full Text] [Related]
35. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
Chen Y; Ma F; Jones N; Deng R; Li C; Li CC
CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):234-246. PubMed ID: 38050329
[TBL] [Abstract][Full Text] [Related]
36. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.
Grimm SW; Einolf HJ; Hall SD; He K; Lim HK; Ling KH; Lu C; Nomeir AA; Seibert E; Skordos KW; Tonn GR; Van Horn R; Wang RW; Wong YN; Yang TJ; Obach RS
Drug Metab Dispos; 2009 Jul; 37(7):1355-70. PubMed ID: 19359406
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of Action of Panaxytriol on Midazolam 1'-Hydroxylation and 4-Hydroxylation Mediated by CYP3A in Liver Microsomes and Rat Primary Hepatocytes.
He F; Zhang W; Zeng C; Xia C; Xiong Y; Zhang H; Huang S; Liu M
Biol Pharm Bull; 2015; 38(10):1470-7. PubMed ID: 26424012
[TBL] [Abstract][Full Text] [Related]
38. The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo.
Zhao P
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):151-64. PubMed ID: 18330044
[TBL] [Abstract][Full Text] [Related]
39. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339
[TBL] [Abstract][Full Text] [Related]
40. Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies.
Treyer A; Ullah M; Parrott N; Molitor B; Fowler S; Artursson P
AAPS J; 2019 Jun; 21(5):77. PubMed ID: 31214810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
